- BPOM export marketing authorization marks a major milestone for Indonesia’s pharmaceutical industry, opening the door to international markets
- BPOM GMP-certified facility with an annual capacity of 6.5 million vials, built for aseptic manufacturing and quality control
- Investment in R&D and the development of Indonesian biopharmaceutical talent reinforces the foundation for industry growth
[Jakarta, Indonesia, November 11th, 2026] — PT Selatox Bio Pharma (Selatox), an Indonesian biopharmaceutical company, announced that it received export marketing authorization from Indonesia’s National Agency of Drug and Food Control (BPOM) on November 3 for Selatox Botulinum Toxin 100u, its botulinum toxin type A product.
Selatox Botulinum Toxin 100u is the first botulinum toxin product manufactured in Indonesia to receive export marketing authorization from BPOM. This milestone represents a significant step forward for Selatox, positioning the company to introduce Indonesian-manufactured botulinum toxin products to international markets.

(Packed Selatox products stored at the company's warehouse in Cikarang, West Java, Indonesia.)
Completed in April 2025, Selatox’s manufacturing facility in Cikarang, West Java, has an annual production capacity of 6.5 million vials. The facility features a Restricted Access Barrier System (RABS) for aseptic filling, automated packaging equipment, and computerized process control systems. It received Good Manufacturing Practice (CPOB/GMP) certification from BPOM in July 2026 and maintains strict quality control standards throughout the manufacturing process, from raw material handling and production to testing and final product release.
Beyond manufacturing, Selatox is working to establish a comprehensive botulinum toxin business encompassing research and development (R&D), production, quality control, and international commercial operations. Its in-house R&D team is advancing formulation research and developing a pipeline of new products. With export marketing authorization now secured, the company plans to pursue opportunities to register Selatox Botulinum Toxin 100u in target markets and expand its network of international partners across a broader range of export markets.

(A Selatox employee inspects product packaging at the company's warehouse in Cikarang, West Java, Indonesia.)
Selatox is also committed to developing Indonesia’s biopharmaceutical talent through academic partnerships with leading universities across the country. By strengthening its research capabilities and investing in skilled professionals, the company aims to support the long-term development of Indonesia’s biopharmaceutical industry.
Daniel Iskandar Wirawan, Plant Manager at Selatox, said, “This export marketing authorization marks an important first step in bringing Indonesian-manufactured botulinum toxin to the global market. We will continue to build Selatox Botulinum Toxin 100u’s competitiveness by maintaining high standards in aseptic manufacturing processes and quality control, while contributing to the advancement of Indonesia’s biopharmaceutical industry.”
— End —
About Selatox
PT Selatox Bio Pharma (Selatox) is a biopharmaceutical company that researches, develops, and manufactures aesthetic biopharmaceutical products. The company aims to become a trusted global manufacturer, backed by rigorous manufacturing management systems and a strong commitment to quality. Its philosophy, “Pursuing the Highest Quality, Delivering the Finest Beauty,” reflects the company’s dedication to providing products that customers and partners can trust.



